CTRI/2019/03/018023已完成1 期
A Multiple-Dose, Pharmacokinetic and Safety Study of Brimonidine Tartrate Ophthalmic Suspension in Healthy Adult Subjects.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy male and female aged 18 to 45 years inclusive having weight at least 50 Kg and having BMI within 18.5 to 29.99 kg per metre square inclusive.
- •2. Provide signed and dated informed consent in accordance with GCP and local legislation prior to any study procedures and adhere to protocol requirements throughout the study period.
- •3. Women of childbearing potential must not be pregnant or lactating (as confirmed by a negative pregnancy test).
排除标准
- •1. Pregnant females or nursing mothers at screening
- •2. Positive screen on hepatitis B surface antigen, antibodies to the hepatitis C virus or antibodies to the human immunodeficiency virus and Rapid plasma reagin test.
- •3. Any clinically significant finding on clinical examination or 12 Lead ECG or laboratory investigations during screening.
- •4. Have any known allergy or sensitivity to the study medications or their components
- •5. Have a condition or be in a situation which in the investigators opinion, may put the subject at a significant risk, may confound study results, or may interfere significantly with the subjects participation in the study.
研究者
相似试验
已完成
1 期
A study in healthy subjects to see the effects of the test medicine on the body when given in fed or fasted state as a multiple doseTransthyretin (TTR) Amyloidosis (ATTR)Digestive SystemISRCTN11628974Eidos Therapeutics, Inc.28
进行中（未招募）
不适用
A Dose-ranging, Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less Than 6 Years of Age: A 4-week, Multicenter, Randomized, Double-Blind Study with a 1-year Open-label, Follow-up Period.Hypertension in children under the age of 6 yearsEUCTR2004-004264-75-BEAstraZeneca Pharmaceuticals125
进行中（未招募）
1 期
A Dose-ranging, Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less Than 6 Years of Age: A 4-week, Multicenter, Randomized, Double-Blind Study with a 1-year Open-label, Follow-up Period.Hypertension in children under the age of 6 yearsEUCTR2004-004264-75-GBAstraZeneca AB93
进行中（未招募）
不适用
A Dose-ranging, Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less Than 6 Years of Age: A 4-week, Multicenter, Randomized, Double-Blind Study with a 1-year Open-label, Follow-up Period.EUCTR2004-004264-75-DEAstraZeneca AB125
进行中（未招募）
不适用
A Dose-ranging, Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less Than 6 Years of Age: A 4-week, Multicenter, Randomized, Double-Blind Study with a 1-year Open-label, Follow-up Period.Hypertension in children under the age of 6 yearsEUCTR2004-004264-75-DKAstraZeneca Pharmaceuticals125